Nexavar Articles
BioAlliance updates on Livatag development
14 May 2013
AVEO/Astellas' kidney cancer drug tivozanib fails to beat Nexavar
14 February 2013
Treatment landscape for thyroid carcinoma will change dramatically through 2021; report
5 February 2013
Bayer's Nexavar continues to dominate advanced liver cancer therapy, as other late-stage trials fail
17 January 2013
Nexavar use in Chinese patients nearly doubled in 2012
19 December 2012
India's IPAB rejects Bayer's "stay petition" regarding Nexavar
18 September 2012
Indian hearings on Bayer Nexavar compulsory license delayed
22 August 2012
Reimbursement and/or budget-related factors restrict use of angiogenesis inhibitor in Brazil and Mexico; Study
28 March 2012
Three “targeted” cancer drugs slightly raise fatal side effects risk, says Dana-Faber Inst
8 February 2012
Final appraisal from UK’s NICE backs improved treatment access for early Alzheimer’s disease; SMC negative for Nexavar
18 January 2011
Bristol-Myers Squibb and Pfizer drop development of apixaban in acute coronary syndrome, but good news for Pfizer with axitinib
22 November 2010
Multinational drugmakers’ sales will represent 92% of Mexico's NSCLC cancer drug Market in 2014
1 August 2010
Bayer/Onyx’s Nexavar disappoints as first-line advanced NSCLC therapy, failing to meet goals in Ph III study
14 June 2010
Pfizer discontinues Ph III trial of Sutent in advanced liver cancer as it fails versus Bayer’s Nexavar
26 April 2010
Rarer Cancer Forum pleads with UK’s NICE to fund Bayer’s Nexavar
25 February 2010
UK’s NICE again rejects Bayer’s Nexavar for advanced liver cancer, but company can, and will, appeal
19 November 2009
US FDA clears two indications for Boehringer Ingelheim’s telmisartan and GSK’s Votrient for renal cancer
20 October 2009
Bayer’s regorafenib shows promise in renal cancer, may fuel Onyx dispute
22 September 2009
Changes predicted in renal cell carcinoma market leaders
15 September 2009
UK’s NICE again refuses Nexavar for liver cancer patients
8 September 2009
Onyx/Bayer initiate Ph III Nexavar trial
3 June 2009
Japan: no added use for Nexavar, Alimta
27 May 2009
Bayer/Onyx
21 May 2009
Onyx asserts right to Ph II drug against Bayer
19 May 2009
NICE's "bizarre" decision
29 April 2009
Bayer licenses Ardea's MEKs for up to $407M
29 April 2009
Bayer hit by charges and falling material science sales in 1st qtr, but pharma division doing well
29 April 2009
Bayer and Onyx halt Nexavar trial
28 April 2009
Novartis' 1st-qtr 2009 results boosted by new products
24 April 2009
Positive HCC data for Y-90 radioembolization
24 April 2009
Afinitor cleared in USA for advanced RCC
1 April 2009
Bayer Yakuhin aiming for $2.06B annual sales
31 March 2009
Sutent cleared for UK kidney cancer patients
30 March 2009
ArQule expands drug candidate into HCC
16 March 2009
Nexavar pushes Onyx back to profit
9 March 2009
Sutent available in England, not Scotland
9 February 2009
Govts pay for good drugs, says Bayer chief
24 November 2008
BTG in up to $307M cancer dealwith Onyx
17 November 2008
Bayer/Onyx' Nexavar boosts OS 44% in HCC
10 November 2008
Pfizer economic study says Sutent cost effective in mRCC
22 September 2008
Protherics begins Ph IIa liver cancer study of Prolarix
1 September 2008
Onyx back in profit for 2nd qtr after sales jump
1 September 2008
Bayer/Onyx initiate Ph III Nexavar trial in liver cancer
1 September 2008
UK cancer charity slams NICE methods
11 August 2008
Bayer's 2nd-qtr 2008 net profit falls 13%
11 August 2008
Stock Commentary - Europe - week to Aug 4, 2008
11 August 2008
Bayer/Onyx' Nexavar cleared for HCC in China
4 August 2008
Strong mid-stage data on Nexavar
9 June 2008
Stock Commentary - Europe - week to June 2, 2008
9 June 2008
Nexavar improves overall survival 47.3%
26 May 2008
Onyx shatters expectations in 1st qtr
19 May 2008
Nexavar excluded from Japan's DPC
5 May 2008
Everolimus trial halted after early PFS gains
10 March 2008
Bayer's 4th-qtr 2007 profit plummets 76% to 67M euros, well below analyst expectations
10 March 2008
Onyx narrows 4th-qtr 2007 loss to $11.7M
3 March 2008
Bayer/Onyx halt Nexavar trial in NSCLC
25 February 2008
Stock Commentary - Europe - week to Feb 18, 2008
25 February 2008
UPDATE: Bayer and Onyx halt Nexavar trial in NSCLC
25 February 2008
Clexane, and Nexavar in RCC approved in Japan
4 February 2008
FDA OKs Nexavar for unresectable HCC
26 November 2007
Nexavar launched in UK for HCC
21 November 2007
EC clears Bayer/Onyx' Nexavar in HCC
5 November 2007
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
